Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02689518 · ClinicalTrials.gov registry record · Phase 4
EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection
A Phase 4 study, sponsored by University of California, San Diego.
- Completed
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
NCT02689518 is a Phase 4 study that has completed, run by University of California, San Diego. The registered enrollment target is 50 participants.
The verdict
NCT02689518, a Phase 4 study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
Study Summary
Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
Interventions
- DRUG Intravitreal aflibercept injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2014-04 |
| Est. Completion | 2019-11-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02689518
The ClinicalTrials.gov registry entry for NCT02689518 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Intravitreal aflibercept injection is the first listed.
NCT02689518 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02689518 about?
NCT02689518 is a clinical study titled "EAGLE: Evaluating Genotypes Using Intravitreal Aflibercept Injection". Clinical and genetic evaluation of individuals treated with intravitreal aflibercept injection (Eylea) for neovascular age-related macular degeneration (wet AMD)
What is the current status of trial NCT02689518?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2014-04. Estimated completion is 2019-11-12.
What interventions are being tested in trial NCT02689518?
The interventions under investigation include: Intravitreal aflibercept injection (DRUG).
Who is sponsoring clinical trial NCT02689518?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.